As per latest concall, Management is expecting a high R&D expense in Q4. Paracetomol & Metformin Sales Price declining. They are keeping the margin but topline is reducing for top products. New facility Commercialization maybe in FY26. They are introducing new Products (FD) in US & applying for approvals in Europe.
Management is not giving guidance. They are talking about a lot of Capex and I can not get a clear picture on how & when it will improve revenue.
I have a small position now but do not have a clarity to increase investment. Any Opinions on how you are tracking thier performance?
Subscribe To Our Free Newsletter |